Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Exp Immunol. 2009 Oct;158(1):1-9. doi: 10.1111/j.1365-2249.2009.03992.x.

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

Author information

  • 1Dipartimento Medico-Chirurgico di Internistica Clinica, Seconda Università degli Studi di Napoli, Naples, Italy.

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed for cancer therapy. Here we review the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy. The efficacy of EGFR-specific mAb in cancer occurs thanks to inhibition of EGFR-generated signalling; furthermore, the effects of antibodies on the immune system seem to play an important role in determining the overall anti-tumour response. In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR.

PMID:
19737224
[PubMed - indexed for MEDLINE]
PMCID:
PMC2759052
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Write to the Help Desk